| scholarly article | Q13442814 |
| P356 | DOI | 10.1080/00325481.2017.1315290 |
| P698 | PubMed publication ID | 28374645 |
| P2093 | author name string | Bindu Chamarthi | |
| Anthony H Cincotta | |||
| P2860 | cites work | Postprandial dysmetabolism and the heart | Q38045547 |
| Focusing on cardiovascular disease in type 2 diabetes mellitus: an introduction to bromocriptine QR. | Q38055296 | ||
| Dopaminergic agonists normalize elevated hypothalamic neuropeptide Y and corticotropin-releasing hormone, body weight gain, and hyperglycemia in ob/ob mice | Q38316225 | ||
| The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis | Q38537377 | ||
| Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study | Q41709013 | ||
| Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes | Q42999133 | ||
| Effect of bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents | Q44980950 | ||
| beta-Cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis | Q45105931 | ||
| Hypothalamic sensing of circulating fatty acids is required for glucose homeostasis | Q45286060 | ||
| Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects | Q47330714 | ||
| Suprachiasmatic nuclei monoamine metabolism of glucose tolerant versus intolerant hamsters | Q48151137 | ||
| Bromocriptine reduces obesity, glucose intolerance and extracellular monoamine metabolite levels in the ventromedial hypothalamus of Syrian hamsters | Q48415286 | ||
| Dopaminergic neurotoxin administration to the area of the suprachiasmatic nuclei induces insulin resistance | Q48565675 | ||
| Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes. | Q51551827 | ||
| Bromocriptine: a novel approach to the treatment of type 2 diabetes. | Q51554471 | ||
| Chronic ventromedial hypothalamic infusion of norepinephrine and serotonin promotes insulin resistance and glucose intolerance. | Q54063921 | ||
| Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration | Q57412996 | ||
| Relevance of Sympathetic Nervous System Activation in Obesity and Metabolic Syndrome | Q21284498 | ||
| Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy | Q26775037 | ||
| Thiazolidinediones and Edema: Recent Advances in the Pathogenesis of Thiazolidinediones-Induced Renal Sodium Retention | Q26851905 | ||
| Adding pioglitazone to insulin containing regimens in type 2 diabetes: systematic review and meta-analysis | Q33476850 | ||
| Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes | Q33932712 | ||
| Thiazolidinediones | Q34346862 | ||
| Restoration of hypothalamic lipid sensing normalizes energy and glucose homeostasis in overfed rats | Q34435140 | ||
| Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes | Q34718312 | ||
| Neuroendocrine and metabolic components of dopamine agonist amelioration of metabolic syndrome in SHR rats | Q35559692 | ||
| Impact of Bromocriptine-QR Therapy on Glycemic Control and Daily Insulin Requirement in Type 2 Diabetes Mellitus Subjects Whose Dysglycemia Is Poorly Controlled on High-Dose Insulin: A Pilot Study | Q35594627 | ||
| Combined thiazolidinedione-insulin therapy: should we be concerned about safety? | Q35887411 | ||
| Insulin resistance and endothelial dysfunction: the road map to cardiovascular diseases | Q36408698 | ||
| Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects | Q36522638 | ||
| Long-term, intermittent, insulin-induced hypoglycemia produces marked obesity without hyperphagia or insulin resistance: a model for weight gain with intensive insulin therapy | Q36527752 | ||
| Sympathetic system activity in obesity and metabolic syndrome | Q36674835 | ||
| The involvement of dopamine in the modulation of sleep and waking | Q36726950 | ||
| Sympathetic overdrive and cardiovascular risk in the metabolic syndrome | Q36754316 | ||
| Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. | Q36919077 | ||
| Insulin-associated weight gain in diabetes--causes, effects and coping strategies | Q36966075 | ||
| Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetes | Q36985135 | ||
| Postprandial hyperglycemia as an etiological factor in vascular failure | Q37464262 | ||
| Attenuated dopaminergic tone in the paraventricular nucleus contributing to sympathoexcitation in rats with Type 2 diabetes | Q37578164 | ||
| Bromocriptine--unique formulation of a dopamine agonist for the treatment of type 2 diabetes | Q37661556 | ||
| Sympathetic nervous activation in obesity and the metabolic syndrome--causes, consequences and therapeutic implications. | Q37695713 | ||
| Review article: Thiazolidinediones and heart failure | Q37724501 | ||
| Sensing the fuels: glucose and lipid signaling in the CNS controlling energy homeostasis | Q37765224 | ||
| Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis | Q37885450 | ||
| Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes | Q37937592 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | type 2 diabetes | Q3025883 |
| P304 | page(s) | 446-455 | |
| P577 | publication date | 2017-04-04 | |
| P1433 | published in | Postgraduate Medicine | Q7234297 |
| P1476 | title | Effect of bromocriptine-QR therapy on glycemic control in subjects with type 2 diabetes mellitus whose dysglycemia is inadequately controlled on insulin | |
| P478 | volume | 129 |
Search more.